Back to School: How biopharma can reboot drug development. Access exclusive analysis here
iDD Biotech granted Calypso exclusive, worldwide rights to CALY-002, a humanized mAb, to
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury